OBJECTIVES: To access and understand the main characteristics of the Reimbursement submission process and HTA recommendations in Brazil METHODS: This is a crossed analysis of secondary data displayed by the Brazilian new technology incorporation committee (CITEC) regarding the quantity and characteristics (disease, submitter, type of health technology, and year of submission) of the submitted protocols versus quantity and characteristics of the recommended health technologies. RESULTS: In 3 years of existence, 216 Health technologies (mean of 48 submissions per year) were appraised by the commission resulting in 22 positive recommendations and XX Negative recommendations. For the reconvened Health technologies, the median time from submission and recommendation was 1 year. Oncology and Rheumatology are the main submissions groups by disease ( 12% and 11% respectively) and Hepatology and Rheumatology are the most recommended groups by disease (18% and 14% respectively). Manufacturers are the main submitters (74%), followed by the own federal government. 5% of the submissions was made by mixed submitters that can be chacterized by research partnerships between manufacturers, academia and government. CONCLUSIONS: This finds suggests that the conduction of HTA recommendation and adoption process is already a reality in Brazil and the decisions are based not anymore only in political issues but are strongly based on clinical and economical issues too. As a new process in the country, modifications as time to response and establishment of a Brazilian ICER during the next years can improve the results for CITEC and submitters.